Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Elotuzumab (Empliciti) is indicated for use in combination with lenalidomide and dexamethasone, or pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received one to three prior therapies, including lenalidomide and a proteasome inhibitor.
• Four systematic reviews/meta-analyses provided an exhaustive analysis of Empliciti's safety and efficacy within the context of multiple myeloma treatment.
• The studies indicate that elotuzumab increases overall survival (OS) by 14% and progression-free survival (PFS) by 20%, particularly when combined with lenalidomide plus dexamethasone or pomalidomide plus dexamethasone.
• Efficacy seems to be especially noted in patients with relapsed/refractory MM, showing a significant reduction in disease progression risk compared to newly diagnosed/untreated MM. However, among various triplet regimens based on pomalidomide and dexamethasone, combinations involving elotuzumab showed lower overall response rates than those containing bortezomib.
• In terms of safety profile, there are concerns about increased risks associated with serious adverse events such as infection or cardiac disorders when using elotuzumab-containing regimens. Another study emphasizes the need for future studies to account for managing these adverse events effectively across monoclonal antibody treatments like this drug class.
• Despite its efficacy benefits over other drugs used for treating multiple myeloma, specifically in increasing OS and PFS rates, careful consideration must be given due to its elevated risk factors.